Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes.
Maria FleseriuRichard J AuchusYona GreenmanSabina ZacharievaEliza B GeerRoberto SalvatoriRosario PivonelloUlla Feldt-RasmussenLaurence KennedyMichael BuchfelderBeverly Mk BillerFredric CohenAnthony P HeaneyPublished in: European journal of endocrinology (2022)
In the first long-term levoketoconazole study, continued treatment through a 12-month maintenance period sustained the early clinical and biochemical benefits in most patients completing EE, without new adverse effects.